ReviewCirculation research2021
COVID-19 and Cardiovascular Disease: From Bench to Bedside.
Review in Circulation research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 206 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
206 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Cardiovascular outcomes in long COVID-19: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2025Pooled it
- Identifying patterns of reported findings on long-term cardiac complications of COVID-19: a systematic review and meta-analysis.BMC medicine · 2023Pooled it
- Single-cell analysis of adult human heart across healthy and cardiovascular disease patients reveals the cellular landscape underlying SARS-CoV-2 invasion of myocardial tissue through ACE2.Journal of translational medicine · 2023Pooled it
- Heart failure during the COVID-19 pandemic: clinical, diagnostic, management, and organizational dilemmas.ESC heart failure · 2022Pooled it
- Surviving the Struggle of COVID-19: Practical Recommendations for Pediatric/Adult Cardiology and Cardiac Surgical Programs in Resource-Limited Settings: a Review.Brazilian journal of cardiovascular surgery · 2022Pooled it
- Genetic Predisposition of Anti-Cytomegalovirus Immunoglobulin G Levels and the Risk of 9 Cardiovascular Diseases.Frontiers in cellular and infection microbiology · 2022Pooled it
- RIC in COVID-19-a Clinical Trial to Investigate Whether Remote Ischemic Conditioning (RIC) Can Prevent Deterioration to Critical Care in Patients with COVID-19.Cardiovascular drugs and therapy · 2022Trial
- Clinico-histopathologic and single-nuclei RNA-sequencing insights into cardiac injury and microthrombi in critical COVID-19.JCI insight · 2022Trial
- Pre-Infection COVID-19 Vaccination and Long-Term Cardiovascular Outcomes in Adults Without Preexisting Cardiovascular Disease: A Retrospective Cohort Study.Health science reports · 2026Article
- Significance and Usefulness of High-Resolution 24-h Electrocardiographic Parameters in Patients With Coronavirus Disease 2019 After Admission: A Prospective Cohort Study.Journal of arrhythmia · 2026Article
- Early Placental Angioactive Response to Maternal SARS-CoV-2 Infection: an Immunohistochemical Study.Reproductive sciences (Thousand Oaks, Calif.) · 2026Article
- Clinical characteristics and risk factors associated with mortality in hospitalized patients with COVID-19 aged 90 years or older.Medicine · 2026Article
- Cardiovascular burden of long coronavirus disease: Clinical challenges and emerging biomarkers.World journal of cardiology · 2026Review
- High incidence of post-discharge cardiovascular mortality after COVID-19 hospitalization: a data-linkage study in Southern Iran.BMC cardiovascular disorders · 2026Article
- Remdesivir in COVID-19: pros and cons.Frontiers in pharmacology · 2026Review
- Toward Precision in Myocardial Injury Management: A Critical Synthesis and the C.A.L.I.B.R.A.T.E. Framework for Biomarker Integration.Clinical Medicine Insights. Cardiology · 2026Review
- Impact of ACEI/ARB use on COVID-19 mortality in patients with ischaemic heart disease: insights from South Korean National health insurance service data.BMC infectious diseases · 2025Article
- From infection to intervention: post-acute sequelae of SARS-CoV-2 infection and cardiovascular risk.Inflammopharmacology · 2025Review
- Epigenetic liquid biopsies reveal endothelial turnover and erythropoiesis in asymptomatic COVID-19.Life science alliance · 2025Article
- A survey of SARS-CoV-2 tropism.Infectious diseases & immunity · 2025Review
146 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
A pandemic of historic impact, coronavirus disease 2019 (COVID-19) has potential consequences on the cardiovascular health of millions of people who survive infection worldwide. Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), the etiologic agent of COVID-19, can infect the heart, vascular tissues, and circulating cells through ACE2 (angiotensin-converting enzyme 2), the host cell receptor for the viral spike protein. Acute cardiac injury is a common extrapulmonary manifestation of COVID-19 with potential chronic consequences. This update provides a review of the clinical manifestations of cardiovascular involvement, potential direct SARS-CoV-2 and indirect immune response mechanisms impacting the cardiovascular system, and implications for the management of patients after recovery from acute COVID-19 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.